Group 1: Market Overview - The National Medical Insurance Administration is advancing the "going out" strategy for Chinese pharmaceuticals and medical devices, with a focus on building a multi-level support network for international procurement by 2026[1] - In 2025, China is expected to approve 76 innovative drugs, with over 150 transactions amounting to more than $130 billion[1] - By 2024, China's medical device exports are projected to account for 8.17% of the global market, maintaining the fourth position worldwide[1] Group 2: Financial Performance - Revenue for medical device manufacturing companies in China is expected to reach 1.42 trillion yuan in 2025, reflecting a year-on-year growth of 5%[1] - As of October 2025, the number of medical device manufacturers in China reached 33,300, an increase of 576 from the end of 2024[1] - The number of effective invention patents in the medical device sector is projected to reach 50,525 by 2024, a year-on-year increase of 21.63%[1] Group 3: Export and Import Trends - From January to October 2025, the export value of IVD instruments, diagnostic equipment, and dental materials was 30.8 billion yuan, 67.4 billion yuan, and 9.3 billion yuan respectively, with year-on-year growth rates of 11.16%, 9.43%, and 12.15%[1] - IVD reagent imports saw a year-on-year decline of 22.89%, indicating reduced reliance on imports, while high-end diagnostic equipment still shows demand[1] Group 4: Stock Market Performance - The North Exchange's pharmaceutical and biological sector saw a weekly increase of 1.18%, with medical devices rising by 1.83%[2] - 85.71% of pharmaceutical and biological stocks on the North Exchange experienced price increases this week[2]

煤炭 业 研 究 2026 年 01 月 24 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -19% -10% 0% 10% 19% 29% 2025-01 2025-05 2025-09 煤炭 沪深300 相关研究报告 《煤价上行回归合理价格，坚定稳煤 价逻辑—行业周报》-2026.1.18 《重视煤价合理才是常态，稳煤价逻 辑依旧—行业周报》-2025.12.21 《煤价合理才是常态，稳煤价逻辑依 旧—行业周报》-2025.12.14 煤价动态波动中寻求合理点位，稳字是核心 ——行业周报 王高展（分析师） 程镱（分析师） wanggaozhan@kysec.cn 证书编号：S0790525070003 chengyi@kysec.cn 证书编号：S0790525090001 本周要闻回顾：煤价动态波动中寻求合理点位，稳字是核心 动力煤方面：动力煤价格微跌，截至 1 月 24 日，秦港 Q5500 动力煤平仓价为 685 元/吨，环比下降 10 元/吨，前期已经完成了我们估算的第四目标价格区间，即 800-860 元区间。目前回调至煤电盈利均分的 750 元价格以下，我们预计未来价 格将逐步修复 ...

人，魔法原子机器人将首秀春晚 ——行业周报 行业走势图 数据来源：聚源 -14% 0% 14% 29% 43% 58% 72% 2025-01 2025-05 2025-09 机械设备 沪深300 机械设备 机械设备 2026 年 01 月 25 日 投资评级：看好（维持） 马斯克表示2026年底或2027年向公众出售人形机器 相关研究报告 《聚氨酯 TPU 结构件：防护减震理想 选择，人形机器人量产落地的"安全 垫"—行业周报》-2026.1.18 《新剑传动启动上市辅导，特斯拉供 应链核心资产有望迎来价值重估 — 行业周报》-2026.1.11 《马斯克宏图的下一个篇章：脑机接 口，2026 年将启动大规模量产，有望 解锁人机协同终极形态—行业周报》 -2026.1.4 | 孟鹏飞（分析师） | 黄雄（分析师） | | --- | --- | | mengpengfei@kysec.cn | huangxiong@kysec.cn | 证书编号：S0790522060001 人形机器人板块：结构性走强，上行趋势明晰 近期人形机器人板块指数呈震荡向上走势，量能温和放大，进入震荡上行通道。 本周（1 月 19 ...

北交所策略专题报告 2026 年 01 月 25 日 铁拓机械借并购进军高端数控机床制造，北证已 49 家并购重组事件 ——北交所并购重组专题报告第十六期 北交所研究团队 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 《高端仪器智能化、数字化取得进展， 2025 年 归 母 净 利 润 预 计 同 比 增 214~237% — 北交所信息更新》 -2026.1.23 《美德乐（920119.BJ）：高精度输送领 军企业，锂电回暖 2025H1 在手订单升 至 18 亿—北交所新股申购报告》 -2026.1.20 《ELSD 打开第二增长曲线，2025 年 预 计 归 母 净 利 润 同 比 +64.48% ～ 85.95%—北交所信息更新》-2026.1.20 北 交 所 研 究 北交所是中小企业并购重组首选地，已 49 家次公布重要并购重组事件 从新"国九条"到"并购六条"，2024 年起，并购重组市场迎来了诸多积极信号。 产业整合、跨界并购，为产业发展注入了新的动力。2025 年 10 月 29 日，中共 北京市委金融委员会办公室制定《北京市关于助力并购重 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The total retail sales in China for 2025 reached CNY 501,202 billion, with a year-on-year growth of +3.7%. December's retail sales showed a modest increase of +0.9% [25][34] - The retail sector is experiencing a gradual recovery, with service retail outperforming goods retail. Online sales are rebounding, while offline supermarkets, convenience stores, and specialty shops are performing relatively steadily [4][27] - The high-end traditional gold market is expanding, with brands like Laopu Gold gaining traction among high-net-worth consumers, supported by strong sales during promotional events [34][38] Summary by Sections Retail Sector Overview - The retail and social service indices reported increases of 2.16% and 3.20% respectively from January 19 to January 23, 2026, with the retail index ranking 16th among 31 sectors [6][15] - The jewelry sector has shown the highest growth, with an increase of 8.66% in the past week and 11.51% year-to-date [18][20] Consumer Trends - Essential consumer goods are stable, with food and oil products performing particularly well. In contrast, optional consumer goods show mixed results, with cosmetics and jewelry performing better than clothing and home appliances [31][33] - The online retail market for physical goods reached CNY 130,923 billion in 2025, growing by +5.2%, accounting for 26.1% of total retail sales [27][30] Investment Recommendations - Focus on high-quality companies in high-demand sectors driven by emotional consumption themes, particularly in gold and jewelry, with recommendations for brands like Laopu Gold, Chao Hong Ji, and Chow Tai Fook [7][41] - Emphasize offline retail companies adapting to market changes and AI-enabled cross-border e-commerce leaders, recommending companies like Yonghui Supermarket and Aiyingshi [7][39] - Highlight domestic beauty brands that innovate in emotional value and safety, recommending brands like Mao Ge Ping and Proya [7][39] - Consider differentiated medical beauty product manufacturers and expanding chain medical institutions, with recommendations for companies like Meili Tianyuan and Aimeike [7][39]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has transitioned from a single product leader to a platform enterprise in the automotive parts industry, with a focus on eight major product lines and an active expansion into emerging fields like robotics. The expected revenue for 2025-2027 is projected to be 296 billion, 359 billion, and 454 billion yuan, with net profits of 28.3 billion, 36.2 billion, and 48.5 billion yuan respectively. The current market valuation corresponds to PE ratios of 51, 40, and 30 times [4][5] Summary by Sections Company Overview - The company has over 40 years of experience in the automotive parts sector, evolving through three key stages: initial entry, business expansion, and rapid growth, particularly in the context of electric vehicles and robotics [17] Business Model and Strategy - The core drivers of the company's sustained growth are binding key customers for volume increases and a platform-based layout that enhances the value per vehicle. The company has successfully partnered with major clients like SAIC-GM, Geely, and Tesla, significantly increasing its per-vehicle value from a few hundred yuan to approximately 30,000 yuan [5][19] Robotics and Automotive Synergy - The company is leveraging its automotive supply chain expertise to enter the humanoid robotics market, which shares significant technological and hardware similarities with automotive systems. The projected market for humanoid robots could reach 140 billion yuan, with a CAGR of 68% from 2026 to 2030 [6][7] Financial Performance and Projections - The company’s revenue and net profit have shown consistent growth, with 2025 projected revenues of 29.6 billion yuan and net profits of 2.83 billion yuan. The company’s gross margin is expected to stabilize around 20% [9][25] Customer Base and Market Position - The company has established a diverse customer base, with Tesla becoming a significant contributor to revenue, accounting for approximately 40% of total revenue by 2023. The company is also expanding its client portfolio to include other major players in the automotive and robotics sectors [19][46] Production Capacity and Efficiency - The company is investing 5 billion yuan to build a core component production base for robotics in Ningbo, while also enhancing its overseas production capabilities to align with customer production schedules [7][55]

行业走势图 数据来源：聚源 -14% 0% 14% 29% 43% 58% 72% 2025-01 2025-05 2025-09 机械设备 沪深300 机械设备 机械设备 2026 年 01 月 25 日 投资评级：看好（维持） 马斯克表示2026年底或2027年向公众出售人形机器 人，魔法原子机器人将首秀春晚 ——行业周报 相关研究报告 《聚氨酯 TPU 结构件：防护减震理想 选择，人形机器人量产落地的"安全 垫"—行业周报》-2026.1.18 《新剑传动启动上市辅导，特斯拉供 应链核心资产有望迎来价值重估 — 行业周报》-2026.1.11 《马斯克宏图的下一个篇章：脑机接 口，2026 年将启动大规模量产，有望 解锁人机协同终极形态—行业周报》 -2026.1.4 | 孟鹏飞（分析师） | 黄雄（分析师） | | --- | --- | | mengpengfei@kysec.cn | huangxiong@kysec.cn | 证书编号：S0790522060001 证书编号：S0790525070005 人形机器人板块：结构性走强，上行趋势明晰 近期人形机器人板块指数呈震荡向上走势，量能温和放大 ...

北交所策略专题报告 2026 年 01 月 25 日 农药落后产能出清加速，聚焦合规龙头集中度与盈利修复 北交所研究团队 ——北交所策略专题报告 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 2026 年 1 月 8 日，财政部、税务总局联合发布《关于调整光伏等产品出口退税 政策的公告》，公告指出自 2026 年 4 月 1 日起，取消光伏等部分产品的出口退税， 产品清单中包括草铵膦、精草铵膦、敌敌畏和烯禾啶等多款农药原药品种；本次 调整主要针对农药原药及中间体，而农药制剂的出口退税政策并未变动。本次政 策精准指向产能过剩和高毒禁限用品种，旨在整治长期存在的"内卷外化"顽疾， 倒逼产业转向以技术、品牌和全球价值链为核心的高质量发展轨道。2026 年 1 月 1 日开始施行的"一证一品"政策，将推动大量违规低价产品退出市场，行业 集中度将进一步提升，拥有丰富登记证资源的头部企业将获得绝对优势，登记证 从"准入许可证"变为核心战略资源；"一证一品"助力农药价格脱离"成本线"， 价格体系有望向更合理的方向修复。随着农药行业景气回暖，北交所公司颖泰生 物业绩也得到改善 ...

北交所策略专题报告 2026 年 01 月 25 日 动力电池回收产业迎政策元年：市场复合增速达 57%，布局北交所稀缺标的 北交所研究团队 ——北交所策略专题报告 | 诸海滨（分析师） | 余中天（分析师） | | --- | --- | | zhuhaibin@kysec.cn | yuzhongtian@kysec.cn | | 证书编号：S0790522080007 | 证书编号：S0790525050003 | 动力电池回收利用暂行办法出台，北证标的提前布局锂电循环 2026 年 1 月 23 日，工信部等六部门联合发布《新能源汽车废旧动力电池回收和 综合利用管理暂行办法》。中国内地的退役锂电池总量由 2020 年的 157,100 吨增 至 2024 年的 455,100 吨，复合年增长率为 30.5%。2020 年至 2024 年，全球处理 量由 338,400 吨增至 1.3 百万吨，复合年增长率为 40.6%。同期，中国内地处理 量由 113,900 吨增至 695,700 吨，复合年增长率为 57.2%。目前北交所内锂电池 回收相关的企业共有四家，截至 2026 年 1 月 23 日总市值 ...

Group 1 - The report highlights the strategic support from the National Medical Insurance Administration for the "going out" strategy of Chinese pharmaceuticals and medical devices, indicating a systematic empowerment phase for international expansion [10][11][12] - By 2025, China is expected to approve 76 innovative drugs, with over 150 transactions for external authorization, amounting to more than 130 billion USD, showcasing the global appeal of Chinese pharmaceutical innovations [11][12] - The medical equipment export market is projected to cover over 190 countries and regions, with a global market share of 8.17% in 2024, ranking China fourth globally [21][31] Group 2 - The report notes that the revenue of medical device manufacturing companies in China is expected to reach 1.42 trillion CNY in 2025, reflecting a year-on-year growth of 5% [16][19] - As of October 2025, the number of medical device manufacturers in China is projected to reach 33,300, indicating a continuous increase in production capacity [19][20] - The number of effective invention patents in the medical device sector is expected to reach 50,525 in 2024, representing a year-on-year growth of 21.63%, which supports innovation in the industry [20][24] Group 3 - The report identifies eight medical device and biopharmaceutical companies listed on the Beijing Stock Exchange, including Danaher Biologics, Beikang, and others, highlighting their market presence [34][30] - Among the 101 companies listed on the New Third Board related to medical devices, 31 are recognized as national-level specialized and innovative "little giant" enterprises, with six expected to achieve a net profit exceeding 70 million CNY in 2024 [34][35] - The report mentions that 14 companies in the medical and biological field are currently awaiting approval on the Beijing Stock Exchange, with an average revenue of 438 million CNY in 2024 [48][51]